Prestige Consumer Healthcare Inc.
PBH evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $2.30B
What it means
What to watch
Prepared research question
What matters most for PBH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PBH
Prestige Consumer Healthcare Inc. (PBH) is a consumer health company that markets over-the-counter (OTC) brands, including the recently acquired Breathe Right® and Anbesol® brands, with a focus on non-prescription wellness products.
Key risk: Forward-looking statement risks
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.30B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Prestige Consumer Healthcare Inc. (PBH) is a consumer health company that markets over-the-counter (OTC) brands, including the recently acquired Breathe Right® and Anbesol® brands, with a focus on non-prescription wellness products.
- Cash and cash equivalents of $89.1M as of June 30, 2026 [sec_mda].
- Total revenue of $265.7M for the latest reported period as of June 30, 2026 [sec].
- Net income of $29.2M for the latest reported period as of June 30, 2026 [sec].
- Shareholders' equity of $1,916.7M as of June 30, 2026 [sec].
- Acquired ten OTC brands from Foundation Consumer Healthcare in March 2026, including Breathe Right® Nasal Strips and Anbesol® [news].
What works
- Strong cash position with $89.1M in cash and cash equivalents as of June 30, 2026, an increase of $25.3M from March 31, 2026 [sec_mda].
- Company believes its cash generated from operations and existing credit facilities will be adequate to finance working capital and capital expenditures through the next twelve months [sec_mda].
- Acquisition of ten established OTC brands (e.g., Breathe Right®, Anbesol®) expands product portfolio and market presence [news].
What to weigh
- The company's financial discussion acknowledges forward-looking statements involve risks, assumptions, and uncertainties that could cause future results to differ materially [sec_mda].
- Principal uses of cash include debt service and share repurchases, which may limit flexibility for other investments [sec_mda].
- The acquisition of ten OTC brands may require integration efforts and could carry execution risks, though no specific challenges are detailed in the provided chunks.
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $89.1 million, an increase of $25.3 million from March 31, 2026.”
SEC MD&A · August 6, 2026
Acquisition of OTC brands from Foundation Consumer Healthcare
“Foundation Consumer Healthcare (FCH) announced today that it has entered into a definitive agreement to sell a portion of its over-the-counter (OTC) consumer health and wellness brands to Prestige Consumer Healthcare Inc. The portfolio will include ten OTC brands, including Breathe Right® Nasal Strips and Anbesol®.”
News · March 20, 2026
Company's belief in adequate financing for next twelve months
“we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months.”
SEC MD&A · August 6, 2026
Risks & what to watch (2)›
Key risks
- Forward-looking statement risks — Management's discussion contains forward-looking statements that involve risks, assumptions, and uncertainties; future results could differ materially [sec_mda].
- Cash use priorities — Principal uses of cash include debt service and share repurchases, which may limit funds for other strategic initiatives [sec_mda].
What to watch
- Integration and performance of the ten newly acquired OTC brands (Breathe Right®, Anbesol®, etc.) from Foundation Consumer Healthcare [news].
- Future quarterly earnings reports and any updates on cash position, revenue, and net income trends [sec_mda].
- Any additional acquisitions or divestitures that could reshape the product portfolio [sec_mda].
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Prestige Consumer Healthcare Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Prestige Consumer Healthcare Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Profitable (positive operating cash flow)
D/E 1.38 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Financials
Short Interest
as of Apr 19, 2026- % of float
- 8.0%
- Days to cover
- 5.8
- Shares short
- 2,692,183
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PBH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Prestige Consumer Healthcare Inc.?
Prestige Consumer Healthcare Inc. (PBH) is a consumer health company that markets over-the-counter (OTC) brands, including the recently acquired Breathe Right® and Anbesol® brands, with a focus on non-prescription wellness products.
Who is the CEO of Prestige Consumer Healthcare Inc.?
Mr. Ronald M. Lombardi CPA is the chief executive officer of Prestige Consumer Healthcare Inc. (PBH).
Where is Prestige Consumer Healthcare Inc. headquartered?
Prestige Consumer Healthcare Inc. (PBH) is headquartered in Tarrytown, NY, United States.
What therapeutic areas does Prestige Consumer Healthcare Inc. focus on?
Prestige Consumer Healthcare Inc. develops therapies across Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Pain, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.